However, IM resistance has become a leading obstacle in clinical CML treatment, which may be ascribed to the mutations and over-expression of BCR–ABL, as well as some BCR–ABL-independent pathways. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.